CSL Seqirus to Present 14 Abstracts at ESWI 2025
CSL Seqirus, a global leader in influenza vaccines, announced it will present 14 abstracts at the European Scientific Working group on Influenza (ESWI) conference, taking place in Valencia from 20 to 23 October 2025. The presentations highlight the value of enhanced seasonal influenza vaccines and reinforce the vaccines’ vital role in protecting public health across Europe and beyond.
Key Data Highlights and Timings
Among the highlights are studies comparing enhanced influenza vaccination strategies with existing programs in older adults, and analyses of vaccine effectiveness against test-confirmed influenza outcomes, including hospitalizations. Notable sessions include:
- A Public Health and Comparative Cost Analysis of Enhanced Influenza Vaccination in Adults Aged >65 years Compared to Current Programmes Across the Nordic Region — 18:00–18:30, 21 October (Poster 238).
- Comparable Vaccine Effectiveness of Adjuvanted and High-Dose Influenza Vaccines in Preventing Test-Confirmed Influenza Outcomes, including Hospitalisation, in Overall and High-Risk Older Adults: A Test-Negative Design Study During 2022–2023 and 2023–2024 — 17:30–19:00, 22 October (Poster 153).
“The data being presented at ESWI this year will highlight the clear effectiveness of enhanced seasonal influenza vaccines,” said Jonathan Anderson, Executive Medical Director, International Regions (Europe and Asia Pacific) at CSL Seqirus. “These data show clearly the benefit enhanced influenza vaccines may have to public health.”
Leadership Commentary and Conference Presence
Pepe Meseguer Perez, Spain and Iberian Cluster Head at CSL Seqirus, emphasized ESWI’s importance as a forum for the vaccine community to review the latest infectious disease research. “ESWI is a critical moment in time for the seasonal influenza vaccine community to come together and discuss the latest research in the infectious diseases space,” he stated. CSL Seqirus’ participation at ESWI’s 10th congress underscores the strength of the data submitted and its commitment to sharing results with the global vaccine community.
Supporting the Next Generation of Scientists
In addition to data presentations, CSL Seqirus is proud to sponsor the 4th Young Scientist Vaccine Innovation Award, recognizing outstanding research by emerging scientists in influenza vaccine development. The award ceremony is scheduled for 23 October, 09:30–10:30. A Satellite Symposium on 21 October, 16:00–17:00, will address “Addressing the Evolving Influenza Landscape: A Public Health Imperative,” further highlighting the company’s role in fostering scientific advancement.
About Seasonal Influenza and the Public Health Context
Seasonal influenza remains a significant health burden, with transmission capable of occurring one day before symptom onset and up to 5–7 days after becoming ill. In Europe alone, seasonal influenza can contribute to tens of thousands of deaths annually. Enhanced vaccines, including adjuvanted and high-dose formulations, aim to improve protection for older adults and high-risk groups, potentially reducing hospitalizations and severe outcomes.
About CSL Seqirus
CSL Seqirus is part of CSL (ASX: CSL) and is one of the world’s largest influenza vaccine providers. With production facilities in the United States, the United Kingdom, and Australia, the company employs egg, cell, and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines across more than 20 countries. For more information, visit CSL.com.
Forward-Looking Statements and Safety Information
The release contains forward-looking statements based on current expectations, which involve risks and uncertainties. Readers should consult local regulatory authorities for product approvals and labeling variations by country. The document includes safety information for FLUAD, CSL Seqirus’ adjuvanted influenza vaccine, noting indications, contraindications, common side effects, and reporting channels for adverse events.
About the Event and Access
This press release, issued from Summit, New Jersey, serves to inform media and investors about CSL Seqirus’ global activities around ESWI 2025. Attendees will have the opportunity to engage with CSL Seqirus experts at the conference and learn about the latest research on enhanced seasonal influenza vaccines.
